Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI may spot the embryos most likely to grow

NCT ID NCT06928337

Knowledge-focused Sponsor: Fairtility Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

Researchers are collecting images of eggs and embryos from time-lapse incubators to train an AI system called CHLOE. The goal is to see if the AI can accurately predict which embryos will reach the blastocyst stage, a key step in IVF. This study involves women aged 18 and older whose embryos are cultured in a compatible incubator. The findings could help improve embryo selection in fertility treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI evaluation of oocytes inside a time-lapse incubator
What this could lead to
If successful, this could improve how clinics select embryos for IVF, potentially increasing the chances of a successful pregnancy.
What could go wrong
This is an early data-collection study, not a treatment trial. The AI's predictions need validation and may not improve clinical outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

May 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Oocyte donors

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women at least 18 years of age. * Embryos or eggs cultured in a time-lapse incubator connected to CHLOE Embryo Viewer. Exclusion Criteria: * Women with autologous eggs

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fertility disorders are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fertility disorders

Contacts and locations

Locations

  • The World Egg and Sperm Bank

    Scottsdale, Arizona, 85260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.